GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bonus BioGroup Ltd (OTCPK:BBIXF) » Definitions » Institutional Ownership

BBIXF (Bonus BioGroup) Institutional Ownership : 0.06% (As of Apr. 26, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Bonus BioGroup Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Bonus BioGroup's institutional ownership is 0.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Bonus BioGroup's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Bonus BioGroup's Float Percentage Of Total Shares Outstanding is 0.00%.


Bonus BioGroup Institutional Ownership Historical Data

The historical data trend for Bonus BioGroup's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bonus BioGroup Institutional Ownership Chart

Bonus BioGroup Historical Data

The historical data trend for Bonus BioGroup can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 0.02 0.02 0.02 0.03 0.03 0.03 0.03 0.03 0.03 0.03

Bonus BioGroup Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Bonus BioGroup Business Description

Traded in Other Exchanges
Address
Matam Advanced, Technology Park, P.O.B 15143, Haifa, ISR, 31905
Bonus BioGroup Ltd is an clinical-stage biotechnology company developing next-generation therapies for a variety of indications in the regenerative medicine field. Its products products, BonoFill and MesenCure.

Bonus BioGroup Headlines